$ASMB
Assembly Biosciences Inc Stock $asmb

$asmb Overview Financials Valuation SEC Filings Company Website

2017 Form 10-K Financial Statement

#000114420418013474 Filed on March 08, 2018

Income Statement

Concept	2017	2016 Q4	2016 Q3
Revenue	$50.00M	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$17.02M	$3.250M	$2.850M
YoY Change	39.62%	10.17%	14.46%
% of Gross Profit
Research & Development	$44.23M	$8.620M	$8.833M
YoY Change	33.64%	64.82%	90.77%
% of Gross Profit
Depreciation & Amortization	$219.0K	$20.00K	$18.00K
YoY Change	173.75%	100.0%	0.0%
% of Gross Profit
Operating Expenses	$61.25M	$11.87M	$8.833M
YoY Change	85.07%	45.11%	90.77%
Operating Profit	-$52.23M		-$11.68M
YoY Change	15.35%		63.98%
Interest Expense	$370.0K	-$300.0K	$100.0K
YoY Change	-7.5%	-169.77%	-80.0%
% of Operating Profit
Other Income/Expense, Net	$368.0K
YoY Change	-7.77%
Pretax Income	-$51.86M	-$12.16M	-$11.57M
YoY Change	15.55%	56.9%	74.84%
Income Tax	-$9.050M	-$620.0K	$0.00
% Of Pretax Income
Net Earnings	-$42.81M	-$11.55M	-$11.57M
YoY Change	-3.28%	49.02%	74.89%
Net Earnings / Revenue	-85.62%
Basic Earnings Per Share
Diluted Earnings Per Share	-$2.412M	-$670.3K	-$671.5K
COMMON SHARES
Basic Shares Outstanding			17.23M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017	2016 Q4	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$119.9M	$53.00M	$58.60M
YoY Change	126.23%	-21.71%	-10.94%
Cash & Equivalents	$82.00M	$28.58M	$23.79M
Short-Term Investments	$37.90M	$24.40M	$34.90M
Other Short-Term Assets	$900.0K	$600.0K	$600.0K
YoY Change	50.0%	-14.81%	-14.93%
Inventory
Prepaid Expenses
Receivables	$2.300M	$0.00
Other Receivables	$0.00
Total Short-Term Assets	$123.1M	$53.60M	$59.30M
YoY Change	129.66%	-21.6%	-10.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$900.0K	$200.0K	$100.0K
YoY Change	350.0%	34.58%	-36.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$3.700M	$2.700M	$8.100M
YoY Change	37.04%	-88.56%	-74.2%
Other Assets
YoY Change
Total Long-Term Assets	$46.20M	$44.54M	$49.87M
YoY Change	3.82%	-31.87%	-31.82%
TOTAL ASSETS
Total Short-Term Assets	$123.1M	$53.60M	$59.30M
Total Long-Term Assets	$46.20M	$44.54M	$49.87M
Total Assets	$169.3M	$98.10M	$109.1M
YoY Change	72.58%	-26.65%	-21.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.100M	$2.400M	$3.800M
YoY Change	-12.5%	71.43%	153.33%
Accrued Expenses	$6.100M	$4.800M	$3.600M
YoY Change	27.08%	135.39%	203.23%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.50M	$7.100M	$7.500M
YoY Change	90.14%	108.65%	182.85%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$40.60M
YoY Change
Total Long-Term Liabilities	$40.60M	$11.12M	$11.60M
YoY Change		-4.14%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.50M	$7.100M	$7.500M
Total Long-Term Liabilities	$40.60M	$11.12M	$11.60M
Total Liabilities	$56.20M	$18.20M	$19.10M
YoY Change	208.79%	21.31%	34.02%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$113.1M	$79.88M	$90.00M
YoY Change
Total Liabilities & Shareholders Equity	$169.3M	$98.10M	$109.1M
YoY Change	72.58%	-26.63%	-21.88%

Cashflow Statement

Concept	2017	2016 Q4	2016 Q3
OPERATING ACTIVITIES
Net Income	-$42.81M	-$11.55M	-$11.57M
YoY Change	-3.28%	49.02%	74.89%
Depreciation, Depletion And Amortization	$219.0K	$20.00K	$18.00K
YoY Change	173.75%	100.0%	0.0%
Cash From Operating Activities	$1.860M	-$11.04M	-$7.860M
YoY Change	-105.33%	102.2%	51.74%
INVESTING ACTIVITIES
Capital Expenditures	$865.0K	-$110.0K	-$40.00K
YoY Change	488.44%	1000.0%
Acquisitions
YoY Change
Other Investing Activities	-$14.78M	$15.78M	$11.35M
YoY Change	-140.67%	-512.01%	-193.11%
Cash From Investing Activities	-$15.64M	$15.67M	$11.32M
YoY Change	-143.21%	-508.07%	-192.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$64.85M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	67.24M	150.0K	0.000
YoY Change	43847.71%		-100.0%
NET CHANGE
Cash From Operating Activities	1.860M	-11.04M	-7.860M
Cash From Investing Activities	-15.64M	15.67M	11.32M
Cash From Financing Activities	67.24M	150.0K	0.000
Net Change In Cash	53.46M	4.780M	3.460M
YoY Change	3544.04%	-151.4%	-120.22%
FREE CASH FLOW
Cash From Operating Activities	$1.860M	-$11.04M	-$7.860M
Capital Expenditures	$865.0K	-$110.0K	-$40.00K
Free Cash Flow	$995.0K	-$10.93M	-$7.820M
YoY Change	-102.84%	100.55%	50.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016	us-gaap	Interest Income Other InterestIncomeOther	1539088	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17020607	USD
CY2016Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	24388403	USD
CY2017Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	3347213	USD
CY2016Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	2435753	USD
CY2017Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	46184933	USD
CY2016Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	44543942	USD
CY2017Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	42691510	USD
CY2016Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	11119651	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-392391	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-600769	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	37914482	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	897400	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	611176	USD
CY2017	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	61245628	USD
CY2016	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	45278461	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-52226878	USD
CY2017	us-gaap	Interest Income Other InterestIncomeOther	983209	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	368081	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-44261562	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12185484	USD
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.41
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.57
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17750380	shares
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17226245	shares
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42600170	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44040746	USD
CY2017	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-615128	USD
CY2016	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-1139861	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18357937	USD
CY2015	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	29655630	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-29655630	USD
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15702646	shares
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29275418	USD
CY2015	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-27033	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-51858797	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-44879234	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28453833	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9050249	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-617672	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	466483	USD
CY2016	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	702797	USD
CY2015	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	27033	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7876584	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	554268	USD
CY2015	asmb	Adjustments To Additional Paid In Capital Cashless Exercise Of Warrants AdjustmentsToAdditionalPaidInCapitalCashlessExerciseOfWarrants	0	USD
CY2015	us-gaap	Trading Securities Unrealized Holding Gain Loss TradingSecuritiesUnrealizedHoldingGainLoss	-821585	USD
CY2015	asmb	Stock Issued During Period Value Common Stock Issued StockIssuedDuringPeriodValueCommonStockIssued	81014989	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5024512	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	152640	USD
CY2016	us-gaap	Trading Securities Unrealized Holding Gain Loss TradingSecuritiesUnrealizedHoldingGainLoss	220816	USD
CY2016	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	0	USD
CY2017	us-gaap	Depreciation Depreciation	219225	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	8601442	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	5024512	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27107526	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-244192	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1386177	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	286224	USD
CY2017	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-84192	USD
CY2016	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-58208	USD
CY2017	us-gaap	Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax	274778	USD
CY2016	us-gaap	Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax	358139	USD
CY2017	asmb	Cashless Exercise Of Warrants CashlessExerciseOfWarrants	0	USD
CY2016	asmb	Cashless Exercise Of Warrants CashlessExerciseOfWarrants	0	USD
CY2017	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	64847354	USD
CY2017	asmb	Accrued Offering Cost Related To Issuance Of Common Stock AccruedOfferingCostRelatedToIssuanceOfCommonStock	2393142	USD
CY2016	asmb	Accrued Offering Cost Related To Issuance Of Common Stock AccruedOfferingCostRelatedToIssuanceOfCommonStock	152640	USD
CY2015	us-gaap	Depreciation Depreciation	64989	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	7876584	USD
CY2017	asmb	Noncash Or Part Noncash Acquisition Other Current Goodwill NoncashOrPartNoncashAcquisitionOtherCurrentGoodwill	0	USD
CY2016	asmb	Noncash Or Part Noncash Acquisition Other Current Goodwill NoncashOrPartNoncashAcquisitionOtherCurrentGoodwill	0	USD
CY2017	asmb	Noncash Or Part Noncash Acquisition Increase Decrease In Payables And Accruals Assumed NoncashOrPartNoncashAcquisitionIncreaseDecreaseInPayablesAndAccrualsAssumed	0	USD
CY2016	asmb	Noncash Or Part Noncash Acquisition Increase Decrease In Payables And Accruals Assumed NoncashOrPartNoncashAcquisitionIncreaseDecreaseInPayablesAndAccrualsAssumed	0	USD
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2016	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	146329	USD
CY2017	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	456097	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1968844	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	555849	USD
CY2015	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-82153	USD
CY2015	us-gaap	Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax	-821585	USD
CY2015	asmb	Cashless Exercise Of Warrants CashlessExerciseOfWarrants	88	USD
CY2015	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	81014989	USD
CY2015	asmb	Accrued Offering Cost Related To Issuance Of Common Stock AccruedOfferingCostRelatedToIssuanceOfCommonStock	554268	USD
CY2015	asmb	Noncash Or Part Noncash Acquisition Other Current Goodwill NoncashOrPartNoncashAcquisitionOtherCurrentGoodwill	-99214	USD
CY2015	asmb	Noncash Or Part Noncash Acquisition Increase Decrease In Payables And Accruals Assumed NoncashOrPartNoncashAcquisitionIncreaseDecreaseInPayablesAndAccrualsAssumed	-99214	USD
CY2015	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-954	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-9050249	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-617672	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	864564	USD
CY2016	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2015	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	150	USD
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	48234454	USD
CY2016	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	7951257	USD
CY2015	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	69781176	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	33456565	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	44294160	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	4983777	USD
CY2017Q1	us-gaap	Licenses Revenue LicensesRevenue	50000000	USD
CY2017Q1	asmb	Development Milestone Payments DevelopmentMilestonePayments	630000000	USD
CY2017Q1	asmb	Commercial Milestone Payments CommercialMilestonePayments	2150000000	USD
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4687115	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4474160	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3384693	shares
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	41450363	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	41261695	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5635	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	194303	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	27287602	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	26824156	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	473056	USD
CY2017	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	33500000	USD
CY2016	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	44300000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	36825138	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	194303	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	0	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	36825138	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	194303	USD
CY2014Q3	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	29823096	USD
CY2014Q3	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	12638136	USD
CY2017Q4	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	0	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1273849	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	409285	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	413823	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	194598	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4518128	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2884000	USD
CY2017Q4	asmb	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	674686	USD
CY2016Q4	asmb	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	916674	USD
CY2017Q4	asmb	Accured General And Administrative Expenses Current AccuredGeneralAndAdministrativeExpensesCurrent	946186	USD
CY2016Q4	asmb	Accured General And Administrative Expenses Current AccuredGeneralAndAdministrativeExpensesCurrent	710412	USD
CY2017Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	0	USD
CY2016Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	241737	USD
CY2015Q4	asmb	Initial Public Offering Value Of Shares Authorized InitialPublicOfferingValueOfSharesAuthorized	150000000	USD
CY2017Q4	asmb	Future Stock Based Compensation Expense Total FutureStockBasedCompensationExpenseTotal	8205796	USD
CY2017Q4	asmb	Future Stock Based Compensation Expense Year Two FutureStockBasedCompensationExpenseYearTwo	5755478	USD
CY2017Q4	asmb	Future Stock Based Compensation Expense Year Three FutureStockBasedCompensationExpenseYearThree	1760834	USD
CY2017Q4	asmb	Future Stock Based Compensation Expense Year Four FutureStockBasedCompensationExpenseYearFour	634516	USD
CY2016Q3	us-gaap	Interest Income Other InterestIncomeOther	378381	USD
CY2016Q4	us-gaap	Interest Income Other InterestIncomeOther	225681	USD
CY2017	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y2M12D
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8601442	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5024512	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7876584	USD
CY2017Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	14614198	USD
CY2017Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	15926562	USD
CY2017Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	15109793	USD
CY2017Q4	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	15595075	USD
CY2016Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	11277152	USD
CY2016Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	10454130	USD
CY2016Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	11678925	USD
CY2016Q4	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	11868254	USD
CY2017Q1	us-gaap	Interest Income Other InterestIncomeOther	136484	USD
CY2017Q2	us-gaap	Interest Income Other InterestIncomeOther	239858	USD
CY2017Q3	us-gaap	Interest Income Other InterestIncomeOther	241326	USD
CY2017Q4	us-gaap	Interest Income Other InterestIncomeOther	365541	USD
CY2016Q1	us-gaap	Interest Income Other InterestIncomeOther	490421	USD
CY2016Q2	us-gaap	Interest Income Other InterestIncomeOther	444605	USD
CY2017Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-137248	USD
CY2017Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-340984	USD
CY2017Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-99068	USD
CY2017Q4	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-37828	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-13930593	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-13598864	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-12272019	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-3007072	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-10988558	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-10152200	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-11574117	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-11546687	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.81
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.78
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.64
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.59
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.67
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.67
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1300000	USD
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1200000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2273421	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17246754	shares
CY2017	us-gaap	License And Services Revenue LicenseAndServicesRevenue	9018750	USD
CY2016	us-gaap	License And Services Revenue LicenseAndServicesRevenue	0	USD
CY2015	us-gaap	License And Services Revenue LicenseAndServicesRevenue	0	USD
CY2017	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	82245	USD
CY2016	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	299741	USD
CY2015	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	0	USD
CY2017	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	148645	USD
CY2016	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	437064	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	40555708	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5229227	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20137974	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17246754	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20137974	shares
CY2015	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	66400	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	137323	USD
CY2017	us-gaap	Revenue Recognition Milestone Method Description RevenueRecognitionMilestoneMethodDescription	the Company is eligible to receive up to approximately $630 million in payments related to seven development milestones and up to approximately $2.15 billion in payments related to 12 commercial development and sales milestones in connection with the successful development and commercialization of licensed compounds for up to six different indications
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2273421	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2017	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	45784935	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2016Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-201827	USD
CY2016Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-142675	USD
CY2016Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-273573	USD
CY2016Q4	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-521786	USD
CY2016Q4	asmb	Deferred Tax Assets Related Party Interest DeferredTaxAssetsRelatedPartyInterest	3962000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	178000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	316000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	77711000	USD
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Use of Estimates</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of consolidated financial statements in conformity with the accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Significant estimates inherent in the preparation of the accompanying consolidated financial statements include recoverability and useful lives (indefinite or finite) of intangible assets, assessment of impairment of goodwill, provisions for income taxes, and the fair value of stock options and warrants granted to employees, consultants, directors, investors, licensors, placement agents and underwriters. In addition, with the Company entering into the Collaboration Agreement in 2017, the Company believes its consolidated financial statements are also impacted by the following accounting estimates and judgments: (i) identifying deliverables under collaboration agreements involving multiple elements and determining whether such deliverables are separable from other aspects of the contractual relationship; (ii) estimating the selling price of deliverables for the purpose of allocating arrangement consideration for revenue recognition; and (iii) estimating the periods over which the allocated consideration for deliverables is recognized.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Receivable Current OperatingLeasesFutureMinimumPaymentsReceivableCurrent	2974537	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Two Years OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears	1193126	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Three Years OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears	827511	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Four Years OperatingLeasesFutureMinimumPaymentsReceivableInFourYears	254136	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Five Years OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears	212625	USD
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Concentrations of Credit Risk</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Financial instruments which potentially subject the Company to credit risk consist primarily of cash, cash equivalents and marketable securities. The Company holds these investments in highly rated financial institutions, and, by policy, limits the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	9610	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	59926000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	9279000	USD
CY2016Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4050000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	77711000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	11119651	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	11119651	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	153200000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	165000000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5600000	USD
CY2017Q4	asmb	Future Stock Based Compensation Expense Year Five FutureStockBasedCompensationExpenseYearFive	54968	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2400000	USD
CY2017	us-gaap	Licenses Revenue LicensesRevenue	50000000	USD
CY2017	us-gaap	Cost Of Reimbursable Expense CostOfReimbursableExpense	4600000	USD
CY2017Q4	asmb	Initial Public Offering Value Of Shares Authorized InitialPublicOfferingValueOfSharesAuthorized	250000000	USD
CY2017Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	800000	shares
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7M6D
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	58571172	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	118741595	USD
CY2017Q4	us-gaap	Income Tax Examination Penalties Accrued IncomeTaxExaminationPenaltiesAccrued	0	USD
CY2016Q4	us-gaap	Income Tax Examination Penalties Accrued IncomeTaxExaminationPenaltiesAccrued	0	USD
CY2017	asmb	Stock Issued During Period Value Common Stock Issued StockIssuedDuringPeriodValueCommonStockIssued	64847354	USD
CY2017	us-gaap	Trading Securities Unrealized Holding Gain Loss TradingSecuritiesUnrealizedHoldingGainLoss	208378	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8601442	USD
CY2017	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2393142	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4872000	USD
CY2016	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2016	asmb	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod		shares
CY2016	asmb	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue
CY2017	asmb	Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested In Period Fair Value1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedInPeriodFairValue1	3000000	USD
CY2017	asmb	Deferred Revenue Amortization Period Over Service Tenure DeferredRevenueAmortizationPeriodOverServiceTenure	P10Y
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	53458124	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1467559	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1983587	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1860081	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34881655	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18697334	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	67240496	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	152640	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	81569257	USD
CY2017Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	46000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	314000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	43577000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5726000	USD
CY2017Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2259000	USD
CY2017Q4	asmb	Deferred Tax Assets Related Party Interest DeferredTaxAssetsRelatedPartyInterest	5604000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15642453	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	36196574	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-64855510	USD
CY2017	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	24700000	USD
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	28400000	USD
CY2017	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	3700000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	68590000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	63718000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	7007802	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2135802	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.026	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.043	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.110	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	0	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	0	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	0.009	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.034	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.167	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.021	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.018	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.003	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.023	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.270	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.255	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.273	pure
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.175	pure
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.014	pure
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2017	asmb	Effective Income Tax Rate Reconciliation Change In Enacted Federal Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedFederalTaxRate	0.477	pure
CY2016	asmb	Effective Income Tax Rate Reconciliation Change In Enacted Federal Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedFederalTaxRate	0	pure
CY2016	asmb	Effective Income Tax Rate Reconciliation Change In Enacted State Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedStateTaxRate	0.075	pure
CY2015	asmb	Effective Income Tax Rate Reconciliation Change In Enacted Federal Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedFederalTaxRate	0	pure
CY2017	asmb	Effective Income Tax Rate Reconciliation Change In Enacted State Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedStateTaxRate	0.002	pure
CY2015	asmb	Effective Income Tax Rate Reconciliation Change In Enacted State Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedStateTaxRate	0	pure
CY2017Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	4900000	USD
CY2015	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	5000000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Receivable Thereafter OperatingLeasesFutureMinimumPaymentsReceivableThereafter	106312	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Receivable OperatingLeasesFutureMinimumPaymentsReceivable	5568247	USD
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	700000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2900000	USD
CY2017	asmb	Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate	0	pure
CY2017Q4	us-gaap	License And Services Revenue LicenseAndServicesRevenue	3315457	USD
CY2017Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	2659613	USD
CY2017Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	2359311	USD
CY2017Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	684369	USD
CY2017Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	11064000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	0	USD
CY2017	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	The TaxActalso permits an indefinite carry forward of net operating losses generated in taxable years ending after December 31, 2017, subject to a utilization limitation of 80% of taxable income.
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y9M18D
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	8600000	USD

Files In Submission

Name	View Source	Status
0001144204-18-013474-index-headers.html	Edgar Link	pending
0001144204-18-013474-index.html	Edgar Link	pending
0001144204-18-013474.txt	Edgar Link	pending
0001144204-18-013474-xbrl.zip	Edgar Link	pending
asmb-20171231.xml	Edgar Link	completed
asmb-20171231.xsd	Edgar Link	pending
asmb-20171231_cal.xml	Edgar Link	unprocessable
asmb-20171231_def.xml	Edgar Link	unprocessable
asmb-20171231_lab.xml	Edgar Link	unprocessable
asmb-20171231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv486659_10k.htm	Edgar Link	pending
tv486659_ex10-16.htm	Edgar Link	pending
tv486659_ex10-17.htm	Edgar Link	pending
tv486659_ex21.htm	Edgar Link	pending
tv486659_ex23-1.htm	Edgar Link	pending
tv486659_ex31-1.htm	Edgar Link	pending
tv486659_ex31-2.htm	Edgar Link	pending
tv486659_ex32-1.htm	Edgar Link	pending
tv486659_ex32-2.htm	Edgar Link	pending
tv486659_img1.jpg	Edgar Link	pending
tv486659_img2.jpg	Edgar Link	pending
tv486659_img3.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ASMB
Assembly Biosciences Inc Stock $asmb

2017 Form 10-K Financial Statement

#000114420418013474 Filed on March 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASMB Assembly Biosciences Inc Stock $asmb

2017 Form 10-K Financial Statement

#000114420418013474 Filed on March 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASMB
Assembly Biosciences Inc Stock $asmb